Novo Nordisk has significantly lowered the cash price of Wegovy. What does this mean for users of the drug in Ireland, and will it have wider implications for the weight-loss drug is administered or treated in Ireland more broadly? Joining Shane Beatty to discuss is Dr Brendan O’Shea, Assistant Professor of Primary Care at Trinity College Dublin & Bernadette Keenan, Committee Member of the Irish Coalition for People Living with Obesity (ICPO).
Newstalk Weekend